Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.21B Buy
10,099,764
+3,141,695
+45% +$363M 0.33% 54
2025
Q4
$732M Buy
6,958,069
+49,959
+0.7% +$4.69M 0.19% 97
2025
Q3
$580M Sell
6,908,110
-1,110,643
-14% -$91.5M 0.15% 119
2025
Q2
$635M Sell
8,018,753
-3,027,965
-27% -$241M 0.18% 102
2025
Q1
$992M Sell
11,046,718
-1,038,802
-9% -$97M 0.3% 54
2024
Q4
$1.2B Sell
12,085,520
-1,184,771
-9% -$122M 0.34% 50
2024
Q3
$1.51B Sell
13,270,291
-525,052
-4% -$62.4M 0.42% 35
2024
Q2
$1.71B Sell
13,795,343
-2,749,204
-17% -$354M 0.5% 27
2024
Q1
$2.18B Sell
16,544,547
-158,153
-0.9% -$19.5M 0.65% 21
2023
Q4
$1.82B Buy
16,702,700
+47,790
+0.3% +$4.96M 0.59% 26
2023
Q3
$1.71B Buy
16,654,910
+8,656
+0.1% +$933K 0.6% 22
2023
Q2
$1.92B Buy
16,646,254
+275,823
+2% +$31.3M 0.67% 21
2023
Q1
$1.74B Buy
16,370,431
+89,910
+0.6% +$9.71M 0.65% 26
2022
Q4
$1.81B Buy
16,280,521
+3,262,048
+25% +$333M 0.7% 24
2022
Q3
$1.12B Sell
13,018,473
-539,761
-4% -$48.2M 0.45% 42
2022
Q2
$1.24B Buy
13,558,234
+3,437,895
+34% +$305M 0.48% 38
2022
Q1
$800M Sell
10,120,339
-1,789,272
-15% -$141M 0.26% 81
2021
Q4
$913M Sell
11,909,611
-493,511
-4% -$39.3M 0.27% 74
2021
Q3
$932M Sell
12,403,122
-1,994,057
-14% -$152M 0.29% 72
2021
Q2
$1.12B Sell
14,397,179
-6,329,727
-31% -$471M 0.33% 53
2021
Q1
$1.52B Sell
20,726,906
-4,513,458
-18% -$333M 0.48% 34
2020
Q4
$1.97B Buy
25,240,364
+4,133,846
+20% +$316M 0.67% 19
2020
Q3
$1.67B Buy
21,106,518
+3,047,565
+17% +$239M 0.64% 23
2020
Q2
$1.33B Sell
18,058,953
-4,990,478
-22% -$376M 0.54% 25
2020
Q1
$1.69B Sell
23,049,431
-3,706,162
-14% -$291M 0.82% 16
2019
Q4
$2.32B Buy
26,755,593
+2,370,160
+10% +$195M 0.88% 14
2019
Q3
$1.96B Sell
24,385,433
-1,088,651
-4% -$87.2M 0.79% 17
2019
Q2
$2.04B Buy
25,474,084
+25,089,127
+6,517% +$1.92B 0.8% 16
2019
Q1
$30.6M Buy
384,957
+105,967
+38% +$7.93M 0.16% 184
2018
Q4
$20.3M Sell
278,990
-3,263
-1% -$230K 0.13% 265
2018
Q3
$19.1M Sell
282,253
-5,365
-2% -$342K 0.1% 318
2018
Q2
$16.7M Buy
287,618
+762
+0.3% +$43K 0.1% 290
2018
Q1
$14.9M Sell
286,856
-12,346
-4% -$667K 0.1% 307
2017
Q4
$16.1M Sell
299,202
-563,969
-65% -$31.3M 0.1% 294
2017
Q3
$52.7M Buy
863,171
+102,715
+14% +$6.23M 0.35% 61
2017
Q2
$46.5M Buy
760,456
+122,428
+19% +$7.45M 0.3% 74
2017
Q1
$38.7M Sell
638,028
-19,272
-3% -$1.17M 0.23% 106
2016
Q4
$36.9M Buy
657,300
+210,415
+47% +$12.3M 0.19% 120
2016
Q3
$26.6M Sell
446,885
-1,909
-0.4% -$112K 0.16% 155
2016
Q2
$24.7M Sell
448,794
-7,357
-2% -$392K 0.15% 168
2016
Q1
$23K Sell
456,151
-111,530
-20% -$5.46M 0.12% 174
2015
Q4
$28.6K Sell
567,681
-968,134
-63% -$48.8M 0.15% 149
2015
Q3
$72.4K Buy
1,535,815
+173,159
+13% +$9.2M 0.41% 39
2015
Q2
$74K Buy
1,362,656
+11,299
+0.8% +$634K 0.4% 43
2015
Q1
$74.1M Sell
1,351,357
-371,883
-22% -$21.1M 0.41% 41
2014
Q4
$93.4M Buy
1,723,240
+243,036
+16% +$13.5M 0.52% 31
2014
Q3
$83.7M Sell
1,480,204
-2,815
-0.2% -$158K 0.52% 33
2014
Q2
$81.9M Sell
1,483,019
-19,547
-1% -$1.07M 0.5% 32
2014
Q1
$81.4M Buy
1,502,566
+73,019
+5% +$3.78M 0.49% 32
2013
Q4
$68.3M Sell
1,429,547
-11,627
-0.8% -$531K 0.44% 40
2013
Q3
$65.5M Sell
1,441,174
-141,596
-9% -$6.46M 0.42% 45
2013
Q2
$70.2M Buy
+1,582,770
New +$70.7M 0.47% 38

Other funds holding MRK

Nuveen's MRK Position: Q1 2026 in Review

Nuveen increased its Merck (MRK) stake by 45% in Q1 2026, buying an estimated $363M and bringing the position to 10,099,764 shares worth $1.21B. The position accounts for 0.33% of the portfolio, ranked #54.

Nuveen first reported a position in MRK in Q2 2013 and has held it in 52 quarters since. The position peaked at $2.32B in Q4 2019. 3,784 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Nuveen held 10,099,764 shares of Merck worth $1.21B as of Q1 2026.
  • Nuveen bought 3,141,695 Merck shares in Q1 2026, an estimated $363M.
  • Merck made up 0.33% of Nuveen's portfolio in Q1 2026, its #54 holding.
  • Nuveen first reported a position in Merck in Q2 2013 and has held it in 52 quarters since.
  • Nuveen's Merck position peaked at $2.32B in Q4 2019.
  • 3,784 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Nuveen's 13F filing for Q1 2026, filed 30 Apr 2026.